One of the missions of the “Make America Healthy Again” platform, set by the newly appointed Secretary of Health and Human Services, Robert F. Kennedy Jr., is addressing childhood chronic diseases.
President Donald Trump signed a new executive order related to this issue, which, according to the White House, affected 30 million children in 2022 alone.
“Autism spectrum disorder now affects 1 in 36 children in the United States—a staggering increase from rates of 1 to 4 out of 10,000 children identified with the condition during the 1980s. Eighteen percent of late adolescents and young adults have fatty liver disease, close to 30 percent of adolescents are prediabetic, and more than 40 percent of adolescents are overweight or obese,” the White House states.
They suggest that some of these issues may be linked to the increased prescription of medications.
A Push for Unbiased Science
As reported by MedPage Today, RFK Jr. has vowed to examine the causes of childhood chronic diseases using “unbiased science.”
“We will convene representatives of all viewpoints to study the causes for the drastic rise in chronic disease,” he stated.
“Some of the possible factors we will investigate were previously considered taboo or insufficiently scrutinized—the childhood vaccine schedule, electromagnetic radiation, glyphosate, other pesticides, ultra-processed foods, SSRIs [selective serotonin reuptake inhibitors] and other psychiatric drugs, PFAS [per- and polyfluoroalkyl substances], PFOA [perfluorooctanoic acid], microplastics—nothing is going to be off-limits.”
In his speech to HHS employees, RFK Jr. emphasized the need for integrity in research: “Let’s use protocols that we all agree on in advance and not alter the outcomes of studies when they’re halfway through [because] they look inconvenient. Let’s depoliticize these issues, reestablish a common ground for action, and renew the search for existential truths with no political impediments and no preconceptions.”
The MAHA Commission’s Role
The executive order signed by Trump outlines a bold initiative to “re-direct our national focus, in both public and private sectors, toward understanding and drastically lowering chronic disease rates and ending childhood chronic disease.”
The newly established MAHA Commission consists of representatives from multiple federal agencies and health organizations, including the FDA, NIH, and CDC. Its primary objectives include revising policies on:
- Nutrition and physical activity
- Healthy lifestyles and over-reliance on medication
- Technological habits and their effects
- Environmental impacts
- Food and drug quality and safety
The commission is also tasked with protecting “expert scientific recommendations from inappropriate influence” and increasing transparency regarding existing data.
Additionally, the order calls for an assessment of the “threats posed” by “over-utilization of medication, certain food ingredients, certain chemicals, and other exposures.” It will also examine the prescribing practices of psychiatric medications such as SSRIs, antipsychotics, mood stabilizers, stimulants, and weight-loss drugs.
Concerns from the Medical Community
According to The Seattle Times, “several Washington physicians agree with the premise of monitoring prescribing practices,” but they also believe that Trump’s order may interfere with the doctor-patient relationship.
Dr. Lelach Rave, interim executive director of the Washington Chapter of the American Academy of Pediatrics, shared her concerns.
“Any parent who has a child who is struggling with depression, anxiety, or psychosis knows how scary that can be. And there’s a lot of harm that comes with having untreated illness,” she said, as per The Seattle Times. “Not that you discount the risks of medications because they’re real as well, but there is real risk with disease.”
What Happens Next?
One hundred days after the order was signed, the commission is expected to submit an initial report assessing “the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors, antipsychotics, mood stabilizers, stimulants, and weight-loss drugs.”
Critics worry that a broad federal policy may result in delays or denial of treatment for children who genuinely need these medications. The ongoing debate raises the question: How can the U.S. improve children’s health while ensuring those in need still receive proper care?
As discussions continue, many are watching closely to see how these policies unfold and what their long-term impact on healthcare might be.
Feel free to share this article with your family and friends to keep the conversation going.
